Denosumab has greater preventive effect on fractures, but increased risk for MACE compared with oral bisphosphonates<\/p>\n<\/h3>\n
By Elana Gotkine HealthDay Reporter<\/b>
\n<\/b><\/p>\n
TUESDAY, Jan. 7, 2025 (HealthDay News) — For dialysis-dependent patients treated for osteoporosis, denosumab is associated with a greater preventive effect on fractures but an increased risk for major adverse cardiovascular events (MACE) compared with oral bisphosphonates, according to a study published online Jan. 7 in the Annals of Internal Medicine<\/em>.<\/p>\n Soichiro Masuda, M.D., Ph.D., from Kyoto City Hospital in Japan, and colleagues examined the risk for cardiovascular events and fracture prevention effects with denosumab versus oral bisphosphonates in dialysis-dependent patients in an observational study using data from a Japanese administrative claims database. The study included 1,032 patients: 658 denosumab users and 374 oral bisphosphonate users.<\/p>\n The researchers found that for MACE, the weighted three-year risk difference was 8.2 percent, with a weighted three-year risk ratio of 1.36 (95 percent confidence interval, 0.99 to 1.87). For composite fractures, the weighted three-year risk difference was \u22125.3 percent, and the weighted three-year risk ratio was 0.55 (95 percent confidence interval, 0.28 to 0.93).<\/p>\n “Given the high risk for cardiovascular events associated with denosumab in dialysis-dependent patients, comparative effectiveness and safety of these medications should be confirmed in future studies,” the authors write.<\/p>\n Abstract\/Full Text (subscription or payment may be required)<\/a><\/p>\n